on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies is participating in the BioConnect Investor conference
DBV Technologies announces the participation of its CEO, Daniel Tassé, in the 4th annual BioConnect Investor Conference. This event, organized by HC Wainwright at Nasdaq, will take place on May 19, 2026, in New York. Daniel Tassé will lead an informal discussion, called a "fireside chat," at 9:00 a.m. EST.
The live webcast of this presentation will be accessible via the DBV Technologies website, in the "Investors" section. A replay will be available for 90 days after the event. This participation underscores DBV Technologies' commitment to the biopharmaceutical sector, particularly in the treatment of food allergies with its VIASKIN® technology.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news